Parameters | Total n (%) | PD-L1 < 3.4 ng/ml n (%) | PD-L1 ≥ 3.4 ng/ml n (%) | P value | PD-L1 < 38 % n (%) | PD-L1 ≥ 38 % n (%) | P value |
---|---|---|---|---|---|---|---|
Overall | 77 (100) | 51 (100) | 26 (100) | – | 51 (100) | 26 (100) | – |
Male gender | 42 (54.5) | 23 (45.1) | 19 (73.1) | 0.020 | 26 (51.0) | 16 (61.5) | 0.379 |
Age > 60 years | 11 (14.3) | 10 (19.6) | 1 (3.8) | 0.087 | 9 (17.6) | 2 (7.7) | 0.316 |
ECOG score ≥ 2 | 4 (5.2) | 1 (2.0) | 3 (11.5) | 0.109 | 2 (3.9) | 2 (7.7) | 0.600 |
Ann Arbor stage | |||||||
I | 41 (53.2) | 31 (60.8) | 10 (38.5) | 0.063 | 30 (58.8) | 11 (42.3) | 0.170 |
II | 36 (46.8) | 20 (39.2) | 16 (61.5) | 21 (41.2) | 15 (57.7) | ||
B symptoms | 22 (28.6) | 12 (23.5) | 10 (38.5) | 0.170 | 13 (25.5) | 9 (34.6) | 0.433 |
LDH > 245 U/L | 18 (23.4) | 10 (19.6) | 8 (30.8) | 0.274 | 10 (19.6) | 8 (30.8) | |
IPI score | |||||||
0–1 | 69 (89.6) | 47 (92.2) | 22 (84.6) | 0.432 | 47 (92.2) | 22 (84.6) | 0.432 |
2 | 8 (10.4) | 4 (7.8) | 4 (15.4) | 4 (7.8) | 4 (15.4) | ||
NKPI score | |||||||
0–1 | 56 (72.7) | 39 (76.5) | 17 (65.4) | 0.302 | 38 (74.5) | 18 (69.2) | 0.623 |
2–3 | 21 (27.3) | 12 (23.5) | 9 (34.6) | 13 (25.5) | 8 (30.8) | ||
Chemotherapy regimen | |||||||
GELOX | 51 (66.2) | 34 (66.7) | 17 (65.4) | 0.910 | 35 (68.6) | 16 (61.5) | 0.534 |
CHOP-L | 26 (33.8) | 17 (33.3) | 9 (34.6) | 16 (31.4) | 10 (38.5) | ||
Treatment response | |||||||
CR | 59 (76.6) | 43 (84.3) | 16 (61.5) | 0.026 | 43 (84.3) | 16 (61.5) | 0.026 |
Non-CR | 18 (23.4) | 8 (15.7) | 10 (38.5) | 8 (15.7) | 10 (38.5) |